Cancer clinical trials in the region Île-de-France
787 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Multiple myeloma
#NCT06953960
#2024-517140-65-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required genetic anomalies
BCL2/6
t(11;14)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Abbvie
Phase 1 / Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT06668493
#2024-514360-70-00
Required histologic types
Upper excretory tract cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
1 recruiting site
Ferring Pharmaceuticals
Phase 1 / Phase 2
Lung cancer
#NCT07491497
#2025-524418-27-00
Partie 2 Cohortes M1, M2 et M3
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
TRIANA Biomedicines, Inc.
Phase 1 / Phase 2
Lymphoma
#NCT07018752
#2024-514954-63-00
Toutes sous études
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
20 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 1 / Phase 2
Colon cancer
Rectal cancer
#NCT06324357
#2023-509566-38-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Breast cancer
Stomach and esophageal cancer
#NCT06324357
#2023-509566-38-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Boehringer Ingelheim
Phase 1 / Phase 2
Lymphoma
#NCT07607925
Required histologic types
B cell lymphoma
Required disease stage
Disseminated (stage III and IV)
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Chemotherapy
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2
Lung cancer
#NCT06043817
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lymphoma
#NCT07519772
#2025-523005-15-00
Lymphome folliculaire
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Lymphoma
#NCT07519772
#2025-523005-15-00
Lymphome diffus à grandes cellules B
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Car-T
Autologous stem cell transplant
Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Merck Sharp & Dohme LLC